Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

861

Participants

Timeline

Start Date

September 16, 2016

Primary Completion Date

October 18, 2018

Study Completion Date

December 31, 2025

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL

Pembrolizumab

Intravenous infusion

DRUG

Axitinib

Oral tablet

DRUG

Sunitinib

Oral capsule

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY